Comprehensive Report: Ganirelix (DB06785) in Assisted Reproductive Technology

1.0 Executive Summary

Ganirelix is a synthetic decapeptide and a potent, third-generation gonadotropin-releasing hormone (GnRH) antagonist. Its primary and approved clinical application is in the field of assisted reproductive technology (ART), specifically for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH). By competitively and reversibly blocking GnRH receptors in the pituitary gland, Ganirelix provides rapid and profound suppression of gonadotropin secretion, allowing for the controlled maturation of multiple ovarian follicles and optimizing the timing for oocyte retrieval.

Pharmacologically, Ganirelix represents a significant advancement over the older class of GnRH agonists. Its direct antagonist action eliminates the initial gonadotropin "flare-up" effect and the need for a prolonged down-regulation period, resulting in substantially shorter, more convenient treatment protocols with a reduced total requirement for gonadotropins. This shift from a prophylactic "pituitary shutdown" model to a precise, "just-in-time" intervention has improved the patient experience and safety profile of COH. A key safety benefit of the GnRH antagonist class, including Ganirelix, is a markedly lower incidence of ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication of ovarian stimulation, when compared to long agonist protocols.

Within its class, Ganirelix is most frequently compared to Cetrorelix. Clinical evidence from numerous studies indicates that both agents achieve comparable live birth and clinical pregnancy rates. However, nuanced differences in their safety and pharmacodynamic profiles have emerged. A consistent body of evidence from large retrospective studies suggests that Cetrorelix may offer superior control of premature LH surges and is associated with a significantly lower risk of moderate-to-severe OHSS compared to Ganirelix. This positions Cetrorelix as a potentially preferable agent for patients with a high-risk profile for OHSS, such as those with polycystic ovary syndrome (PCOS).

Ganirelix remains a cornerstone of modern ART protocols, offering a reliable and effective option for a broad range of patients. The choice between GnRH antagonists is a matter of clinical risk stratification based on individual patient characteristics. The therapeutic landscape continues to evolve, with the development and clinical investigation of orally active, non-peptide GnRH antagonists poised to introduce a new paradigm in patient convenience, potentially reshaping the future role of injectable formulations like Ganirelix.

2.0 Introduction: The Role of GnRH Analogues in Controlled Ovarian Hyperstimulation

2.1 The Hypothalamic-Pituitary-Gonadal (HPG) Axis and the Challenge of Premature Luteinization

The human reproductive cycle is governed by a finely tuned neuroendocrine system known as the hypothalamic-pituitary-gonadal (HPG) axis. At its apex, the hypothalamus secretes gonadotropin-releasing hormone (GnRH) in a pulsatile fashion.[1] This pulsatile release stimulates the gonadotroph cells of the anterior pituitary gland to synthesize and secrete two critical gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).[1] During the follicular phase of the menstrual cycle, FSH promotes the growth and development of ovarian follicles, which in turn produce increasing amounts of estradiol.

In a natural cycle, as a dominant follicle matures and estradiol levels rise, a positive feedback mechanism is triggered at the level of the hypothalamus and pituitary. This culminates in a massive, transient release of GnRH, which elicits a surge in LH secretion from the pituitary.[1] The mid-cycle LH surge is the pivotal event that initiates the final stages of oocyte maturation (resumption of meiosis), ovulation (rupture of the follicle and release of the oocyte), and luteinization of the follicular remnant to form the corpus luteum.[1]

The primary goal of controlled ovarian hyperstimulation (COH) in ART is to override the natural selection of a single dominant follicle, instead promoting the concurrent growth of multiple follicles to yield a cohort of mature oocytes for retrieval. This is achieved through the administration of exogenous gonadotropins, primarily FSH. However, this very process creates a significant clinical challenge. The supraphysiological levels of estradiol produced by the numerous developing follicles can trigger the HPG axis's positive feedback loop prematurely, inducing an endogenous LH surge before the majority of follicles have reached optimal size and oocyte maturity.[3] Such a premature LH surge leads to untimely ovulation, the retrieval of immature oocytes unsuitable for fertilization, and ultimately, cancellation of the ART cycle.[1] Therefore, effective suppression of the endogenous LH surge is an indispensable component of all modern COH protocols.

2.2 Evolution of Pituitary Suppression: From GnRH Agonists to Antagonists

The first generation of drugs developed to prevent the premature LH surge were GnRH agonists, such as leuprolide and triptorelin. These molecules are structurally similar to native GnRH and function by binding to and initially stimulating the GnRH receptor. This initial stimulation results in a transient "flare-up" of FSH and LH secretion.[1] However, with continuous, non-pulsatile exposure, GnRH agonists lead to the desensitization and down-regulation of pituitary GnRH receptors over a period of one to three weeks. This prolonged process effectively uncouples the pituitary from hypothalamic control, creating a state of profound hypogonadotropic hypogonadism and preventing any subsequent LH surge.[7] While highly effective, the long down-regulation protocols associated with GnRH agonists have several disadvantages, including a lengthy treatment duration (often 2-3 weeks before stimulation can even begin), the potential for ovarian cyst formation during the flare phase, and hypoestrogenic side effects like hot flushes during the down-regulation period.[9]

The development of GnRH antagonists, including Ganirelix, marked a significant paradigm shift in pituitary suppression for ART. Unlike agonists, these molecules are engineered to bind competitively to the pituitary GnRH receptors without activating them.[11] This mechanism provides an immediate, direct, and reversible blockade of GnRH action, leading to a rapid suppression of gonadotropin secretion within hours of administration.[1] This fundamental pharmacological difference translates into a profound strategic change in the clinical management of COH. The need for a long pre-stimulation down-regulation phase is eliminated. Instead of a prolonged, prophylactic "pituitary shutdown," antagonists allow for a more precise, "just-in-time" intervention. Treatment is initiated mid-follicular phase, only when the risk of a premature LH surge becomes imminent.[14] This approach directly results in a significantly shorter overall treatment duration, a lower cumulative dose of required gonadotropins, and an improved safety profile, particularly a reduced risk of OHSS.[9] This evolution reflects a move towards more patient-friendly, efficient, and safer ART protocols, optimizing the treatment pathway without compromising efficacy.

3.0 Physicochemical Characteristics and Formulation

3.1 Identification and Nomenclature

Ganirelix is a well-characterized small molecule therapeutic agent used in reproductive medicine. It is identified by a standardized set of chemical and regulatory identifiers to ensure precision in research, clinical practice, and manufacturing.

• Generic Name: Ganirelix [1]
• DrugBank ID: DB06785 [1]
• Type: Small Molecule [1]
• CAS Number: The primary Chemical Abstracts Service (CAS) Registry Number for Ganirelix is 124904-93-4.[1] A deprecated CAS number, 123246-29-7, is also noted in some databases.[17]
• Synonyms and Development Codes: Throughout its development and commercialization, Ganirelix has been known by several names and codes, including its originator code Org 37462, research code RS 26306, and various brand names such as Orgalutran, Antagon, and Fyremadel.[1]

3.2 Chemical Structure and Synthesis

Ganirelix is a synthetic decapeptide, meaning it is a peptide composed of ten amino acids. It is a structural analogue of native GnRH, which has been extensively modified to optimize its pharmacological properties.[1] The chemical structure of Ganirelix is defined by specific, non-natural amino acid substitutions at positions 1, 2, 3, 6, 8, and 10 of the native GnRH peptide backbone.[2]

The full chemical name, reflecting its amino acid sequence, is N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N9,N10-diethyl-D-homoarginyl-L-leucyl-N9,N10-diethyl-L-homoarginyl-L-prolyl-D-alaninamide.[18]

• Chemical Formula: C80​H113​ClN18​O13​ [1]
• Monoisotopic Mass: 1568.8423035 Da [1]
• Molecular Weight (as acetate): 1570.4 Da (anhydrous free base) [12]

These complex substitutions are not arbitrary; they are the result of deliberate molecular engineering designed to confer specific advantages over the native hormone. The modifications enhance the molecule's stability against enzymatic degradation by peptidases, which rapidly cleave native GnRH (half-life of 2-4 minutes).[6] Furthermore, these structural changes dramatically increase the molecule's binding affinity for the GnRH receptor. Studies have demonstrated that Ganirelix possesses a ninefold higher receptor-binding affinity compared to endogenous GnRH, with a dissociation constant (

KD​) of 0.4 nM versus 3.6 nM for GnRH.[12] This combination of high affinity and high stability is the molecular basis for its potent and sustained antagonistic activity, which allows for a clinically practical once-daily dosing regimen.

The manufacturing process for Ganirelix involves solid-phase peptide synthesis, a standard method for producing synthetic peptides. This process involves sequentially adding protected amino acids to a growing peptide chain that is anchored to a solid resin support. A detailed protocol describes the use of an automated synthesizer, specific protecting groups for amino acid side chains (e.g., t-butyl for serine), and defined chemical programs for deprotection and coupling steps, followed by cleavage from the resin and extensive purification using chromatographic techniques like reversed-phase high-performance liquid chromatography (HPLC).[18]

3.3 Formulation and Presentation

For clinical use, Ganirelix is formulated as its acetate salt, Ganirelix Acetate.[3] It is supplied as a sterile, colorless, ready-to-use aqueous solution packaged in a single-dose, pre-filled glass syringe, intended exclusively for subcutaneous administration.[2]

Each pre-filled syringe contains a standard dose of 250 mcg of Ganirelix Acetate in a 0.5 mL volume.[14] The formulation includes several excipients to ensure stability, solubility, and isotonicity. These include mannitol (23.5 mg), glacial acetic acid (0.1 mg), and water for injection. The pH of the final solution is adjusted to approximately 5 using acetic acid and/or sodium hydroxide.[14] The product is stored at controlled room temperature and protected from light.[21]

4.0 Clinical Pharmacology

4.1 Pharmacodynamics (Mechanism of Action)

The pharmacological activity of Ganirelix is centered on its interaction with the gonadotropin-releasing hormone receptor (GnRHR), a G-protein coupled receptor located on the surface of gonadotroph cells in the anterior pituitary gland.[1]

• Receptor Antagonism: Ganirelix functions as a direct, competitive antagonist at the GnRHR.[1] It binds with high affinity to the receptor, thereby physically blocking the binding of endogenous GnRH secreted from the hypothalamus.[4] This competitive inhibition prevents the activation of the receptor and its downstream intracellular signal transduction pathways, which are normally responsible for triggering gonadotropin synthesis and release.[1]
• Physiological Effect: The immediate consequence of this receptor blockade is a rapid, profound, and reversible suppression of the pituitary's secretion of both LH and FSH.[1] This effect modulates the HPG axis, preventing the premature LH surge that would otherwise compromise a COH cycle.[1] The suppression of pituitary LH secretion is consistently more pronounced than that of FSH.[1] Data from clinical studies demonstrate that after the last 0.25 mg dose, serum LH concentrations are maximally decreased by approximately 74%, while FSH concentrations are decreased by 32%.[1]
• Key Differentiating Features: A hallmark of Ganirelix's antagonist mechanism is the absence of an initial stimulatory phase, or "flare effect".[1] Unlike GnRH agonists, which initially mimic GnRH and cause a surge in gonadotropin release before inducing desensitization, Ganirelix produces immediate suppression. This avoids the potential for agonist-induced ovarian cyst formation and other complications associated with the flare. Furthermore, the effect of Ganirelix is highly reversible. Following discontinuation of treatment, the competitive blockade ceases, and pituitary function is restored. Serum LH and FSH levels typically return to pre-treatment values within 48 hours, allowing for precise timing of the final oocyte maturation trigger with exogenous hCG.[1]

4.2 Pharmacokinetics (ADME Profile)

The clinical utility and dosing regimen of Ganirelix are directly informed by its absorption, distribution, metabolism, and excretion (ADME) profile.

• Absorption: Following subcutaneous injection, Ganirelix is absorbed rapidly and extensively. The mean absolute bioavailability is high, at approximately 91.1%, indicating that the vast majority of the administered dose reaches systemic circulation.[1] Peak serum concentrations ( Cmax​) are typically achieved within 1 to 2 hours (Tmax​) after administration.[1] With once-daily dosing of 250 mcg, steady-state serum concentrations are reached after three days of treatment.[1] Pharmacokinetic studies have shown that the drug's exposure, as measured by peak concentrations and area under the curve (AUC), increases in a dose-proportional manner within the range of 125 to 500 mcg.[2]
• Distribution: Ganirelix distributes into a mean volume of distribution (Vd​) of approximately 43.7 liters following intravenous administration.[2] In human plasma, it is moderately bound to proteins, with an in vitro protein binding of 81.9%.[2]
• Metabolism: After administration, the parent Ganirelix molecule is the major active compound found in plasma.[2] The drug undergoes metabolic breakdown into smaller peptide fragments. The primary metabolites that have been identified are the 1-4 peptide and the 1-6 peptide, which are observed predominantly in the feces.[2] The liver is a recognized site of metabolism.[28]
• Excretion: Ganirelix and its metabolites are eliminated from the body through two main routes. The majority is excreted in the feces (approximately 75.1%), with a smaller portion excreted in the urine (approximately 22.1%).[2] Urinary excretion is largely complete within 24 hours, while fecal excretion plateaus after about 192 hours (8 days).[2] The mean elimination half-life ( t1/2​) after multiple subcutaneous doses is approximately 16.2 hours.[24]

The pharmacokinetic profile, particularly the elimination half-life, is the central determinant of the entire clinical protocol for Ganirelix. A half-life of approximately 16 hours is long enough to support a convenient once-daily dosing schedule but short enough that it necessitates strict patient compliance to maintain therapeutic concentrations. This is the scientific basis for the clinical guideline that the interval between two injections should not exceed 30 hours.[14] Exceeding this window, which corresponds to just under two drug half-lives, risks allowing the serum concentration to fall below the minimum effective level required to suppress an LH surge, potentially leading to treatment failure. Conversely, this relatively short half-life is also advantageous, as it allows for rapid clearance of the drug and a swift recovery of pituitary responsiveness (within 48 hours) after the final dose, which is essential for the subsequent hCG trigger to effectively induce final oocyte maturation.[4] Thus, this single pharmacokinetic value directly influences the drug's efficacy, safety, and the practical design of the treatment regimen.

Parameter	Single Dose (250 mcg)	Multiple Doses (250 mcg/day)
Bioavailability	~91.1%	Not Applicable
Tmax​ (Peak Plasma Time)	1.1 hr	1.1 hr
Cmax​ (Peak Plasma Conc.)	14.8 ng/mL	11.2 ng/mL
AUC (Area Under Curve)	96 ng·hr/mL	77.1 ng·hr/mL (over 24h)
Vd​ (Volume of Distribution)	43.7 L (IV dose)	Not Applicable
t1/2​ (Elimination Half-life)	12.8 hr	16.2 hr
Protein Binding	81.9%	81.9%
Table 1: Summary of Ganirelix Pharmacokinetic Parameters. Data compiled from sources.2

5.0 Clinical Efficacy and Therapeutic Application in ART

5.1 Approved Indication and Dosing Regimen

The clinical use of Ganirelix is highly specific and targeted within the context of ART.

• Indication: Ganirelix is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH).[1] Its purpose is to prevent premature ovulation, thereby allowing a cohort of ovarian follicles to reach optimal maturity before oocyte retrieval.[3]
• Standard Dosing and Administration: The standard and approved dosage is 250 mcg of Ganirelix administered subcutaneously once daily.[5] The injection is typically self-administered into the subcutaneous tissue of the upper leg or the abdomen around the navel.[14] To prevent lipoatrophy, a localized loss of fat tissue, patients are instructed to rotate the injection site with each dose.[14]
• Initiation and Duration of Treatment: The timing of Ganirelix initiation is crucial and is determined by the patient's ovarian response to gonadotropin stimulation. Treatment is started during the mid-to-late follicular phase. Clinical protocols typically specify initiating Ganirelix on day 5 or day 6 of stimulation with follicle-stimulating hormone (FSH) or the long-acting FSH analogue, corifollitropin alfa.[14] The decision to start may be adjusted based on ultrasound monitoring of follicular growth (number and size of follicles) and/or serum estradiol concentrations.[14] Daily administration of Ganirelix continues until the day that criteria for triggering final oocyte maturation are met. This final maturation is induced by an injection of human chorionic gonadotropin (hCG).[14] The average duration of Ganirelix treatment in pivotal clinical trials was 5.4 days.[31]

5.2 Evidence from Clinical Trials

The efficacy of Ganirelix has been robustly established in multiple adequate and well-controlled clinical studies.

• Dose-Finding and Efficacy Studies: Initial multicenter, randomized, dose-finding studies evaluated Ganirelix doses ranging from 62.5 mcg to 2000 mcg in women undergoing COH with recombinant FSH.[2] These trials demonstrated a dose-dependent suppression of serum LH. The 250 mcg dose was identified as optimal, as it effectively prevented premature LH surges while being associated with the highest rates of pregnancy and implantation.[2]
• Comparative and Confirmatory Trials: Subsequent large, randomized trials confirmed the efficacy and safety of the 250 mcg dose, often using a long GnRH agonist protocol as a reference treatment.[25] These studies established that Ganirelix, when used with recombinant FSH or corifollitropin alfa, is an effective strategy for preventing premature luteinization.[14] Furthermore, clinical data have demonstrated that Ganirelix is safe and effective for use in women undergoing multiple ART treatment cycles.[14]
• Ongoing Research: The clinical investigation of Ganirelix continues. For instance, an active Phase 4 clinical trial (NCT05954962) is currently recruiting participants to compare the efficacy of Ganirelix versus micronized natural progesterone for the prevention of LH peaks during ovarian stimulation, indicating ongoing efforts to refine and optimize COH protocols.[35]

5.3 Application in Specific Patient Subgroups

While Ganirelix is broadly indicated for COH, its use in specific patient populations with distinct physiological characteristics has been a subject of clinical interest and research.

• Poor Ovarian Responders (POR): Women with diminished ovarian reserve who respond poorly to stimulation present a significant clinical challenge. For this population, the GnRH antagonist protocol is often considered a suitable and potentially advantageous option. A key benefit is the avoidance of the profound pituitary suppression associated with long agonist protocols, which may be detrimental in patients who already have a compromised follicular cohort. Studies suggest that for PORs, a GnRH antagonist protocol can yield comparable cumulative live birth rates to alternative strategies like repeated minimal stimulation cycles, but with a significantly shorter time to achieve a live birth.[36] Some clinical reports also suggest that patients who were low responders on a GnRH agonist protocol may exhibit an improved response when switched to an antagonist protocol.[37] However, high-quality, direct comparative data between Ganirelix and Cetrorelix specifically within the POR population is limited, and meta-analyses have concluded there is insufficient evidence to recommend one over the other in this subgroup.[38]
• Polycystic Ovary Syndrome (PCOS): Women with PCOS are characterized by hyperandrogenism, ovulatory dysfunction, and often a high antral follicle count, which places them at a significantly elevated risk for developing OHSS during COH. For this reason, GnRH antagonist protocols are now widely considered the standard of care for PCOS patients. The protocol's ability to significantly reduce the incidence of OHSS compared to long agonist protocols, without compromising pregnancy rates, is a major clinical advantage.[41] The rapid suppression of LH by an antagonist can also be particularly beneficial in PCOS patients, who often have elevated baseline LH levels.[44] As with poor responders, there is a lack of robust, large-scale, randomized trials directly comparing Ganirelix and Cetrorelix in a purely PCOS population, though comparative studies in general IVF populations often include PCOS patients.[45]

6.0 Safety, Tolerability, and Risk Management

6.1 Comprehensive Adverse Effect Profile

The safety profile of Ganirelix has been well-characterized through extensive clinical trials and post-marketing surveillance. The majority of adverse effects are mild, transient, and related to the injection itself or the underlying physiological effects of COH.

• Very Common (≥1/10): The most frequently reported adverse event is a local skin reaction at the site of injection. This typically manifests as redness, with or without swelling, and is transient, generally resolving within 4 hours of administration.[8] Comparative studies have shown that Ganirelix has better local tolerance than some subcutaneous GnRH agonist formulations, with one trial reporting local reactions in 12% of Ganirelix-treated cycles versus 25% in the agonist group.[14]
• Common (≥1/100 to <1/10): Adverse events in this category are often related to the COH process itself. They include gynecological abdominal pain (reported in up to 4.8% of patients), headache (3.0%), ovarian hyperstimulation syndrome (OHSS) (2.4%), vaginal bleeding (1.8%), and nausea (1%).[21] Injection site reactions beyond transient redness are reported in approximately 1.1% of patients.[30]
• Uncommon (≥1/1,000 to <1/100): A general feeling of malaise has been reported as an uncommon side effect.[23]
• Very Rare (<1/10,000): Serious hypersensitivity reactions are very rare but have been reported during post-marketing surveillance. These can include generalized reactions such as rash, facial swelling, dyspnea, urticaria, angioedema, and anaphylaxis (including anaphylactic shock), and may occur as early as the first dose.[4]

System Organ Class	Frequency	Adverse Reaction
Immune System Disorders	Very Rare	Hypersensitivity reactions (e.g., rash, facial swelling, dyspnea, anaphylaxis, angioedema, urticaria)
Nervous System Disorders	Common	Headache
Gastrointestinal Disorders	Common	Nausea, Abdominal Pain
Reproductive System and Breast Disorders	Common	Gynecological Abdominal Pain, Ovarian Hyperstimulation Syndrome (OHSS), Vaginal Bleeding
General Disorders and Administration Site Conditions	Very Common	Local skin reaction at injection site (redness, swelling)
	Common	Injection site reaction (pain, irritation)
	Uncommon	Malaise
Table 2: Summary of Adverse Reactions Associated with Ganirelix. Data compiled from sources.21

6.2 Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is an iatrogenic complication of COH characterized by cystic ovarian enlargement and a fluid shift from the intravascular to the third space, which can lead to ascites, pleural effusion, hemoconcentration, and thromboembolic events. It is a known risk in any COH cycle and is listed as a common adverse event for Ganirelix, with an incidence of 2.4% in key clinical studies.[21] Patients should be counseled to immediately report symptoms such as severe abdominal or pelvic pain, bloating, nausea, vomiting, diarrhea, or rapid weight gain.[46]

The risk of OHSS with Ganirelix must be understood within a broader clinical context. The introduction of the GnRH antagonist class represented a major step forward in OHSS prevention. Meta-analyses consistently show that antagonist protocols are associated with a significantly lower risk of OHSS compared to the traditional long GnRH agonist protocols.[9] This is a first-order safety benefit of the entire drug class. However, within this safer class, a more nuanced risk profile has emerged from direct comparative studies. Multiple large, retrospective cohort analyses have reported a statistically significant higher incidence of moderate-to-severe OHSS in patients treated with Ganirelix compared to those treated with Cetrorelix.[48] This creates a clinical risk hierarchy: while any antagonist protocol is generally safer than an agonist protocol regarding OHSS, the available evidence suggests that for a patient with a high a priori risk of OHSS (e.g., PCOS, high antral follicle count, young age), Cetrorelix may represent the safer therapeutic choice.

6.3 Contraindications, Warnings, and Precautions

The use of Ganirelix is subject to several absolute contraindications and important warnings to ensure patient safety.

Contraindications:

• Pregnancy: Ganirelix is contraindicated in women who are known or suspected to be pregnant. It is classified as Pregnancy Category X.[27] Due to its antigonadotropic properties, it can interfere with the maintenance of early pregnancy. Animal studies in rats and rabbits have demonstrated an increased incidence of litter resorption when the drug was administered at the time of implantation.[14]
• Breast-feeding: It is not known if Ganirelix is excreted in human breast milk. Its use is contraindicated during lactation.[14]
• Hypersensitivity: Ganirelix is contraindicated in patients with a known hypersensitivity to Ganirelix itself, to any of its excipients, to native GnRH, or to any other GnRH analogue.[23]
• Renal or Hepatic Impairment: The use of Ganirelix is contraindicated in patients with moderate or severe renal or hepatic impairment. The pharmacokinetics, safety, and efficacy have not been studied in these populations, and they were excluded from pivotal clinical trials.[14]

Warnings and Precautions:

• Hypersensitivity and Allergic Conditions: As serious hypersensitivity reactions have been reported, special care should be taken in women with signs and symptoms of active allergic conditions. Due to a lack of clinical experience, treatment with Ganirelix is not advised in women with severe allergic conditions.[23]
• Latex Allergy: A critical packaging-related warning concerns the rigid needle shield of the pre-filled syringe. It contains dry natural rubber, a derivative of latex, which can cause severe allergic reactions in individuals with latex sensitivity.[5]
• Patient Weight: The safety and efficacy of Ganirelix have not been formally established in women weighing less than 50 kg or more than 90 kg, as these populations were not extensively studied in clinical trials.[14]
• Prescribing Authority: Ganirelix should only be prescribed by physicians who are experienced in the treatment of infertility.[14]

6.4 Drug Interaction Profile

The potential for drug-drug interactions with Ganirelix is not fully characterized, as formal interaction studies have not been conducted.

• Formal Studies: No dedicated in vivo or in vitro drug-drug interaction studies have been performed for Ganirelix.[1]
• Pharmacodynamic Interactions: A clinically relevant pharmacodynamic interaction exists with exogenous gonadotropins. Because Ganirelix suppresses the pituitary's endogenous gonadotropin secretion, the response to exogenous FSH may be altered. This may necessitate dose adjustments of the administered gonadotropins during the COH cycle to achieve the desired ovarian response.[2]
• Database Information: Drug interaction databases list potential moderate interactions with other hormonal agents commonly used in ART, including human chorionic gonadotropin (hCG), gonadorelin (a GnRH agonist used for diagnostic purposes or as a trigger), menotropins, and urofollitropin.[57] The clinical significance of these listed interactions in the context of a standard COH protocol is generally managed by the protocol design itself. No severe or major drug interactions are noted.[53]

7.0 Comparative Analysis and Clinical Context

7.1 Ganirelix versus GnRH Agonists (e.g., Triptorelin, Leuprolide)

The introduction of GnRH antagonists like Ganirelix provided a distinct alternative to the long-standing GnRH agonist protocols. Direct comparative trials have highlighted several key differences that have reshaped clinical practice.

• Treatment Protocol and Patient Convenience: The most significant advantage of the Ganirelix protocol is the dramatic reduction in treatment duration and complexity. Compared to a long GnRH agonist protocol, which requires initiation in the luteal phase of the preceding cycle, the Ganirelix regimen is substantially shorter. One large randomized study found the average treatment duration was 9 days for the Ganirelix arm versus 26 days for the triptorelin arm.[10] This shorter protocol is associated with a significantly lower total dose of required recombinant FSH (e.g., a median of 450 IU less) and fewer injections, enhancing patient convenience and reducing treatment burden.[10]
• Efficacy: In terms of primary efficacy outcomes, GnRH antagonist protocols have proven to be non-inferior to long agonist protocols. Large-scale studies and meta-analyses have consistently found no statistically significant difference in ongoing pregnancy rates or live birth rates between the two approaches.[10] Implantation rates have also been shown to be comparable.[10]
• Safety and Tolerability: The most compelling advantage of Ganirelix over GnRH agonists lies in its superior safety profile. The incidence of OHSS, particularly moderate to severe forms, is significantly lower in antagonist cycles.[9] This is a critical factor in clinical decision-making, especially for high-risk patients. In terms of tolerability, Ganirelix has also demonstrated improved local tolerance. The percentage of subjects experiencing at least one local skin reaction was found to be twofold lower with Ganirelix compared to a subcutaneous triptorelin formulation (11.9% vs. 24.1%).[10]

7.2 Ganirelix versus Cetrorelix

Within the GnRH antagonist class, Ganirelix and Cetrorelix are the two most widely used agents. While they share the same fundamental mechanism of action, they are distinct molecules with subtle but potentially clinically relevant differences in their pharmacological and clinical profiles.

• Pharmacology and Formulation: Both are synthetic decapeptide GnRH antagonists administered via subcutaneous injection.[37] Ganirelix is supplied as a ready-to-use liquid in a pre-filled syringe, whereas the standard Cetrotide formulation is a lyophilized powder that requires reconstitution before administration.[60] They differ by one to two amino acids in their structure, which may contribute to differences in their pharmacokinetic profiles and receptor interactions.[61] For the standard 0.25 mg daily dose, Ganirelix has a slightly shorter reported half-life (around 16 hours) compared to Cetrorelix (around 20 hours), though data can vary between studies.[29]
• Efficacy - LH Suppression and Pregnancy Outcomes: The primary endpoint for both drugs is the effective prevention of a premature LH surge. While both are highly effective, a growing body of evidence from large retrospective cohort studies suggests that Cetrorelix may provide more robust LH suppression. These studies have consistently reported a lower incidence of premature LH elevations (defined as serum LH ≥10 U/L) in patients treated with Cetrorelix compared to Ganirelix.[49] Despite this difference in surrogate hormonal endpoints, the ultimate clinical outcomes appear to be equivalent. The majority of large-scale studies and meta-analyses have concluded that there is no statistically significant difference in clinical pregnancy rates or live birth rates between the two antagonists.[48] However, a few smaller studies, particularly in populations with diminished ovarian reserve, have noted a non-significant trend towards lower pregnancy rates with Ganirelix, a finding that warrants further investigation in prospective trials.[65]
• Safety - Ovarian Hyperstimulation Syndrome (OHSS): The most consistent and clinically significant difference observed between the two agents is in their safety profile regarding OHSS. Multiple large, independent retrospective studies have reported a statistically significant higher incidence of moderate-to-severe OHSS in cycles using Ganirelix compared to those using Cetrorelix.[48] This finding suggests that while both antagonists are safer than agonists, Cetrorelix may offer an additional margin of safety in preventing this serious complication.
• Patient-Reported Outcomes: Patient experience with the injections may differ slightly. Anecdotal reports and qualitative descriptions note that Cetrotide can sometimes cause a transient, localized, hive-like reaction (pruritus and erythema) at the injection site, which is generally considered a common and benign response.[59] Conversely, some patients have reported that the needle on the Ganirelix pre-filled syringe feels "less smooth" or requires more pressure to inject.[59]

The choice between Ganirelix and Cetrorelix is therefore not a simple matter of one being universally superior. It is a nuanced clinical decision that requires a careful stratification of the patient's individual risk profile. Given that the primary efficacy endpoint of a live birth is largely equivalent between the two drugs, the decision-making process should heavily weigh the secondary outcomes of safety and hormonal control. For a patient with a high a priori risk of OHSS (e.g., a young woman with PCOS and a high antral follicle count), the consistent evidence demonstrating a lower OHSS risk with Cetrorelix makes it a logically preferable first-line choice. In this scenario, the clinician can select the agent with the superior safety profile without compromising the chances of a successful pregnancy. For a normal or poor responder with a low risk of OHSS, Ganirelix remains a robustly effective and appropriate option. The choice becomes one of balancing these clinical data points with factors like drug availability, cost, and patient/physician preference.

Feature	Ganirelix	Cetrorelix
Mechanism of Action	Competitive GnRH receptor antagonist	Competitive GnRH receptor antagonist
Dosing Regimen	250 mcg SC daily	250 mcg SC daily OR 3 mg single SC dose
Half-Life (multiple dose)	~16.2 hours	~20.6 hours
LH Surge Control	Highly effective, but some studies show a higher rate of LH elevations (≥10 U/L) compared to Cetrorelix.	Highly effective, with evidence suggesting superior LH surge suppression and a lower incidence of premature LH elevations.
Live Birth Rate	Comparable to Cetrorelix in most large-scale studies and meta-analyses.	Comparable to Ganirelix in most large-scale studies and meta-analyses.
OHSS Incidence	Significantly lower than GnRH agonists. Evidence from multiple large studies indicates a higher risk of moderate-to-severe OHSS compared to Cetrorelix.	Significantly lower than GnRH agonists. Evidence from multiple large studies indicates a lower risk of moderate-to-severe OHSS compared to Ganirelix.
Patient Tolerability	Generally well-tolerated. Some anecdotal reports of the needle feeling "less smooth."	Generally well-tolerated. Associated with a higher rate of transient, localized, hive-like skin reactions.
Table 3: Comparative Profile of Ganirelix and Cetrorelix. Data compiled from sources.29

8.0 Regulatory and Market Landscape

8.1 Regulatory History and Global Approvals

Ganirelix has received marketing authorization from major regulatory agencies worldwide, establishing its role as a standard-of-care medication in ART.

• United States (FDA): Ganirelix was first approved by the U.S. Food and Drug Administration (FDA) on July 29, 1999, under the brand name Antagon.[17] This was a pivotal approval that introduced the GnRH antagonist protocol to the U.S. market. Marking a significant step in increasing accessibility and competition, the first Abbreviated New Drug Application (ANDA) for a generic version of Ganirelix Acetate Injection was approved by the FDA on November 30, 2018.[69]
• European Union (EMA): In Europe, Ganirelix received its initial marketing authorization from the European Medicines Agency (EMA) on May 16, 2000, under the brand name Orgalutran.[3] Following the expiration of its market exclusivity, a generic version, Ganirelix Gedeon Richter, was granted a marketing authorization valid throughout the EU on July 15, 2022.[17]
• Other Regions: Ganirelix is approved and available in numerous other countries, including Australia and Canada, where it holds a prescription-only status.[3]

8.2 Commercial Landscape: Brand and Generic Availability

The market for Ganirelix has evolved from a single-source product to a competitive landscape with multiple suppliers.

• Originator and Brand Names: The original developer of Ganirelix was Organon. The product has been marketed globally under several brand names, most notably Orgalutran (marketed by Merck Sharp & Dohme/Organon), Antagon, and Fyremadel (marketed by Ferring Pharmaceuticals).[1]
• Generic Manufacturers: The entry of generics has significantly impacted the market. Numerous pharmaceutical companies now manufacture and market generic Ganirelix Acetate injection. These include Sun Pharmaceutical Industries (whose product is commercialized in the U.S. by Ferring), Fresenius Kabi, Meitheal Pharmaceuticals, Amphastar Pharmaceuticals, Gland Pharma Limited, Lupin Pharmaceuticals, and Xiromed.[22]
• Market Context: Ganirelix and Cetrorelix are the dominant injectable GnRH antagonists used in ART.[60] They are part of the broader GnRH analogue market, which also includes GnRH agonists and has applications beyond infertility, such as in oncology (prostate cancer) and gynecology (endometriosis, uterine fibroids). The global GnRH analogue market was valued at approximately USD 4 billion in 2023-2024 and is projected to experience steady growth, driven by the rising prevalence of these conditions and increasing access to advanced medical treatments.[76] North America currently represents the largest geographical market for these therapeutics.[76]

8.3 Future Outlook: The Emergence of Oral GnRH Antagonists

The next significant evolution in GnRH antagonist therapy is already underway with the development of non-peptide, small-molecule antagonists that are orally active. Compounds such as elagolix and relugolix have been developed and approved for conditions like endometriosis and uterine fibroids, and their application in ART is now being actively investigated.[13]

These oral agents offer a transformative advantage in patient convenience and treatment burden, replacing the need for daily subcutaneous injections with a simple oral tablet.[80] They share the favorable pharmacological profile of injectable antagonists, including a rapid, reversible onset of action without a flare effect.[80] Early clinical trials are evaluating their efficacy and safety for ovulation suppression during COH protocols, with initial results suggesting they may be a viable alternative to injectables.[82]

The potential widespread adoption of effective and safe oral GnRH antagonists for IVF could represent a major paradigm shift. The primary driver for this shift would not necessarily be superior clinical efficacy—as injectable antagonists are already highly effective—but rather the profound improvement in the patient experience. The physical and psychological burden of daily injections is a significant aspect of the ART journey for many patients. Eliminating this requirement could fundamentally alter patient and physician preference, potentially relegating injectable formulations like Ganirelix to a second-line or niche role in the future. This highlights a key dynamic in pharmaceutical evolution, where advancements in drug delivery and patient-centered care can be as disruptive as improvements in molecular efficacy.

9.0 Expert Synthesis and Clinical Recommendations

Ganirelix has firmly established its place as a cornerstone therapy in modern assisted reproductive technology. As a potent GnRH antagonist, it provides a highly effective, safe, and efficient method for preventing premature LH surges during controlled ovarian hyperstimulation. Its development marked a significant clinical advancement over the cumbersome and less patient-friendly long GnRH agonist protocols, offering shorter treatment durations, reduced gonadotropin requirements, and a superior safety profile, most notably a lower risk of ovarian hyperstimulation syndrome.

The clinical evidence robustly supports the use of Ganirelix in a broad spectrum of patients undergoing ART. However, the therapeutic landscape is nuanced, particularly in its comparison with the other leading GnRH antagonist, Cetrorelix. While extensive clinical data confirm that both agents yield comparable live birth rates in the general IVF population, the choice between them should be guided by a careful, evidence-based assessment of individual patient risk profiles. A consistent signal from multiple large observational studies indicates that Cetrorelix is associated with a lower incidence of moderate-to-severe OHSS and may provide more stringent control over premature LH elevations.

Based on this synthesis, the following clinical recommendations are proposed:

1. For the general IVF population with a normal predicted ovarian response and low risk of OHSS, Ganirelix and Cetrorelix can be considered clinically equivalent options for preventing premature LH surges, with the choice being guided by factors such as cost, availability, and physician/patient preference regarding formulation (ready-to-use liquid vs. powder for reconstitution).
2. For patients with a high a priori risk of OHSS, such as those with Polycystic Ovary Syndrome (PCOS), a high antral follicle count, or a history of high response to stimulation, the evidence supports the preferential use of Cetrorelix. Its demonstrated association with a lower risk of OHSS provides a meaningful safety advantage without compromising the primary efficacy outcome of achieving a live birth.
3. Regardless of the antagonist chosen, clinicians must adhere to strict dosing schedules, emphasizing to patients the critical importance of the once-daily injection timing to prevent breakthrough LH surges, a direct consequence of the drug's pharmacokinetic profile.

In conclusion, Ganirelix is an indispensable tool in the armamentarium of the reproductive endocrinologist. It is a testament to the progress made in optimizing ART protocols for improved safety and patient experience. The field, however, remains dynamic. The ongoing clinical development of oral GnRH antagonists represents the next frontier, with the potential to further enhance patient-centered care. Clinicians should remain abreast of these developments, as they may redefine the standard of care for pituitary suppression in ART within the next decade, potentially shifting the role of highly effective injectable agents like Ganirelix.

Works cited

1. Ganirelix: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 11, 2025, https://go.drugbank.com/drugs/DB06785
2. FOR SUBCUTANEOUS USE ONLY ... - accessdata.fda.gov, accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021057s010lbl.pdf
3. Ganirelix - Wikipedia, accessed August 11, 2025, https://en.wikipedia.org/wiki/Ganirelix
4. Ganirelix Acetate Injection (250 mcg/0.5 mL) | Mechanism of Action, accessed August 11, 2025, https://organonpro.com/en-us/product/ganirelix-acetate-injection/mechanism-of-action/
5. Ganirelix (subcutaneous route) - Side effects & dosage - Mayo Clinic, accessed August 11, 2025, https://www.mayoclinic.org/drugs-supplements/ganirelix-subcutaneous-route/description/drg-20064001
6. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine - PubMed Central, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10201293/
7. A Comparison between GnRH Agonist Long and GnRH Antagonist Protocol for In vitro Fertilization: A Review - The Science Publishers, accessed August 11, 2025, http://thesciencepublishers.com/biomed_lett/files/v3i1-BML20170224%20(5).pdf
8. Local tolerance, pharmacokinetics, and dynamics of ganirelix (Orgalutran®) administration by Medi-Jector® compared to conventional needle injections | Human Reproduction | Oxford Academic, accessed August 11, 2025, https://academic.oup.com/humrep/article/15/2/245/555180
9. Gonadotrophin-releasing hormone antagonists versus GnRH agonist in subfertile couples undergoing assisted reproductive technology | Cochrane, accessed August 11, 2025, https://www.cochrane.org/evidence/CD001750_gonadotrophin-releasing-hormone-antagonists-versus-gnrh-agonist-subfertile-couples-undergoing
10. Comparable clinical outcome using the GnRH antagonist ganirelix ..., accessed August 11, 2025, https://academic.oup.com/humrep/article/16/4/644/3114026
11. go.drugbank.com, accessed August 11, 2025, https://go.drugbank.com/drugs/DB06785#:~:text=Ganirelix%20aims%20to%20suppress%20premature,secretion%20is%20rapid%20and%20reversible.
12. Ganirelix and the prevention of premature luteinizing hormone surges - PMC, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10201301/
13. Gonadotropin-releasing hormone antagonist - Wikipedia, accessed August 11, 2025, https://en.wikipedia.org/wiki/Gonadotropin-releasing_hormone_antagonist
14. Ganirelix Gedeon Richter, INN-ganirelix, accessed August 11, 2025, https://ec.europa.eu/health/documents/community-register/2024/20241009164263/anx_164263_en.pdf
15. Ganirelix Gedeon Richter - EMA, accessed August 11, 2025, https://www.ema.europa.eu/en/documents/product-information/ganirelix-gedeon-richter-epar-product-information_en.pdf
16. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the preve, accessed August 11, 2025, https://academic.oup.com/humrep/article-pdf/16/4/644/19569518/160644.pdf
17. Ganirelix | C80H113ClN18O13 | CID 16130957 - PubChem, accessed August 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/16130957
18. GANIRELIX | 124904-93-4 - ChemicalBook, accessed August 11, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9775895.htm
19. en.wikipedia.org, accessed August 11, 2025, https://en.wikipedia.org/wiki/Ganirelix#:~:text=Ganirelix%20acetate%20(or%20diacetate)%2C,assisted%20reproduction%20to%20control%20ovulation.
20. Label: FYREMADEL- ganirelix acetate injection, solution - DailyMed, accessed August 11, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0908b5-3551-47fd-95f7-3669b0dff7f1
21. Ganirelix: Uses, Side Effects, Dosage & More - GoodRx, accessed August 11, 2025, https://www.goodrx.com/ganirelix/what-is
22. Ganirelix Acetate Injection - Meitheal Pharmaceuticals, accessed August 11, 2025, https://www.meithealpharma.com/our-products/44
23. Orgalutran, INN-ganirelix, accessed August 11, 2025, https://ec.europa.eu/health/documents/community-register/2017/20170411137536/anx_137536_en.pdf
24. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/10593372/
25. Ganirelix Acetate Injection - accessdata.fda.gov, accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021057s024lbl.pdf
26. Antagon, Orgalutran (ganirelix) dosing, indications, interactions, adverse effects, and more, accessed August 11, 2025, https://reference.medscape.com/drug/ganirelix-342757
27. Ganirelix Monograph for Professionals - Drugs.com, accessed August 11, 2025, https://www.drugs.com/monograph/ganirelix.html
28. Ganirelix : Indications, Uses, Dosage, Drugs Interactions, Side effects - Medical Dialogues, accessed August 11, 2025, https://medicaldialogues.in/generics/ganirelix-2726844
29. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and ..., accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11768417/
30. Ganirelix Acetate Injection (250 mcg/0.5 mL) | Patient Education - Organon Pro, accessed August 11, 2025, https://organonpro.com/en-us/product/ganirelix-acetate-injection/patient-education/
31. Ganirelix Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 11, 2025, https://www.drugs.com/dosage/ganirelix.html
32. Ganirelix: Drug information, accessed August 11, 2025, http://maadi-clinical.byethost8.com/d/topic.htm?path=ganirelix-drug-information
33. Ganirelix Uses, Side Effects & Warnings - Drugs.com, accessed August 11, 2025, https://www.drugs.com/mtm/ganirelix.html
34. Infertility, Subfertility Completed Phase Trials for Ganirelix (DB06785) | DrugBank Online, accessed August 11, 2025, https://go.drugbank.com/indications/DBCOND0048349/clinical_trials/DB06785?phase=&status=completed
35. In-Vitro Fertilization Recruiting Phase 4 Trials for Ganirelix (DB06785) | DrugBank Online, accessed August 11, 2025, https://go.drugbank.com/indications/DBCOND0038038/clinical_trials/DB06785?phase=4&status=recruiting
36. Cumulative Live Birth Rate and Cost-Effectiveness Analysis of Gonadotropin Releasing Hormone-Antagonist Protocol and Multiple Minimal Ovarian Stimulation in Poor Responders - Frontiers, accessed August 11, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.605939/full
37. IVF Medication Protocols for Ovarian Stimulation with Antagonists ..., accessed August 11, 2025, https://www.advancedfertility.com/blog/ivf-medication-protocols-for-ovarian-stimulation-with-antagonists
38. What is the optimal GnRH antagonist protocol for ovarian stimulation ..., accessed August 11, 2025, https://academic.oup.com/humupd/article/29/3/307/6967440
39. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta- - Oxford Academic, accessed August 11, 2025, https://academic.oup.com/humupd/article-pdf/29/3/307/50276459/dmac040.pdf
40. What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/36594696/
41. Live birth rate of gonadotropin-releasing hormone antagonist versus luteal phase gonadotropin-releasing hormone agonist protocol in IVF/ICSI: a systematic review and meta-analysis, accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10941349/
42. Is a GnRH Antagonist Protocol Better in PCOS Patients? A Meta-Analysis of RCTs - Research journals - PLOS, accessed August 11, 2025, https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0091796
43. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type | Human Reproduction Update | Oxford Academic, accessed August 11, 2025, https://academic.oup.com/humupd/article/23/5/560/3965313
44. Cetrotide®: GnRH Antagonist for cycle control - Merck Healthcare, accessed August 11, 2025, https://hcp.merckgroup.com/en/fertility/portfolio/therapeutics/cetrotide.html
45. A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome | Request PDF - ResearchGate, accessed August 11, 2025, https://www.researchgate.net/publication/246410534_A_randomised_comparison_of_ganirelix_and_cetrorelix_use_in_ICSI_cycle_of_women_with_polycystic_ovary_syndrome
46. Ganirelix (Antagon, Fyremadel): Uses, Side Effects, Interactions ..., accessed August 11, 2025, https://www.webmd.com/drugs/2/drug-75166/ganirelix-subcutaneous/details
47. Ganirelix injection - Cleveland Clinic, accessed August 11, 2025, https://my.clevelandclinic.org/health/drugs/20358-ganirelix-injection
48. [Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles] - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/31801718/
49. Effects of cetrorelix versus ganirelix in gonadotropin-releasing hormone antagonist cycles for preventing premature luteinizing hormone surges and on clinical outcomes of IVF-ET cycles - ResearchGate, accessed August 11, 2025, https://www.researchgate.net/publication/337798481_Effects_of_cetrorelix_versus_ganirelix_in_gonadotropin-releasing_hormone_antagonist_cycles_for_preventing_premature_luteinizing_hormone_surges_and_on_clinical_outcomes_of_IVF-ET_cycles
50. (PDF) Comparison of pregnancy outcomes and safety between ..., accessed August 11, 2025, https://www.researchgate.net/publication/390762956_Comparison_of_pregnancy_outcomes_and_safety_between_cetrorelix_and_ganirelix_in_IVFICSI_antagonist_protocols_a_retrospective_cohort_study
51. Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/40297130/
52. Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study - Frontiers, accessed August 11, 2025, https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2025.1492441/full
53. Ganirelix: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 11, 2025, https://www.rxlist.com/ganirelix/generic-drug.htm
54. Ganirelix Acetate: Generic, Fertility Uses, Side Effects, Dosage - MedicineNet, accessed August 11, 2025, https://www.medicinenet.com/ganirelix_acetate/article.htm
55. Ganirelix Gedeon Richter 0.25 mg/0.5 mL solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc) | 14260, accessed August 11, 2025, https://www.medicines.org.uk/emc/product/14260/smpc
56. GANIRELIX THERAMEX (ganirelix (as acetate)) 250 μg/0.5 mL solution for injection - Medsinfo, accessed August 11, 2025, https://medsinfo.com.au/api/documents/Theramex_Ganirelix___PI?format=pdf
57. Follicle stimulating hormone/ganirelix Interactions - Drugs.com, accessed August 11, 2025, https://www.drugs.com/drug-interactions/follicle-stimulating-hormone-ganirelix.html
58. Ganirelix Interactions Checker - Drugs.com, accessed August 11, 2025, https://www.drugs.com/drug-interactions/ganirelix.html
59. IVF Antagonist Protocol: A Guide to Cetrotide and Ganirelix - Dandi Fertility, accessed August 11, 2025, https://dandifertility.com/blogs/blog/guide-to-cetrotide-and-ganirelix
60. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy - MDPI, accessed August 11, 2025, https://www.mdpi.com/1424-8247/18/1/36
61. GnRH Antagonists Produce Differential Modulation of the Signaling ..., accessed August 11, 2025, https://www.mdpi.com/1422-0067/20/22/5548
62. Cetrotide vs Ganirelix Comparison - Drugs.com, accessed August 11, 2025, https://www.drugs.com/compare/cetrotide-vs-ganirelix
63. www.frontiersin.org, accessed August 11, 2025, https://www.frontiersin.org/journals/reproductive-health/articles/10.3389/frph.2025.1492441/full#:~:text=Cetrorelix%20excels%20in%20LH%20control,cases%20requiring%20swift%20LH%20suppression.
64. Comparison of pregnancy outcomes and safety between cetrorelix ..., accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12034626/
65. The effect of cetrorelix vs ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels - IMR Press, accessed August 11, 2025, https://www.imrpress.com/journal/ceog/36/3/pii/1630635714776-889891766
66. The effect of cetrorelix vs ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 - IMR Press, accessed August 11, 2025, https://article.imrpress.com/journal/CEOG/36/3//1630635714776-889891766.pdf
67. prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI - Oxford Academic, accessed August 11, 2025, https://academic.oup.com/humrep/article/16/8/1676/624678
68. Drug Approval Package: Antagon (Ganirelix Acetate) NDA# 21-057, accessed August 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21057_Antagon.cfm
69. 2018 First Generic Drug Approvals - FDA, accessed August 11, 2025, https://www.fda.gov/drugs/first-generic-drug-approvals/2018-first-generic-drug-approvals
70. Ferring Pharmaceuticals adds two products to its robust reproductive health portfolio in the U.S., accessed August 11, 2025, https://ferringusa.com/?press=ferring-pharmaceuticals-adds-two-products-to-its-robust-reproductive-health-portfolio-in-the-u-s
71. Ganirelix Gedeon Richter | European Medicines Agency (EMA), accessed August 11, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ganirelix-gedeon-richter
72. Ganirelix - brand name list from Drugs.com, accessed August 11, 2025, https://www.drugs.com/ingredient/ganirelix.html
73. Ganirelix acetate - KEGG DRUG - (www.genome.jp)., accessed August 11, 2025, https://www.genome.jp/dbget-bin/www_bget?D04302
74. Expanding Access to Women's Health Fresenius Kabi Launches Generic Fertility Treatment, accessed August 11, 2025, https://www.fresenius-kabi.com/us/news-and-events/expanding-access-to-women-s-health-fresenius-kabi-launches-gener
75. Fresenius Kabi launches two generic drugs in the U.S. | FSE, accessed August 11, 2025, https://www.fresenius.com/node/6634
76. Gnrh Agonists And Antagonists Drugs Market - Market Growth Rate ..., accessed August 11, 2025, https://www.datamintelligence.com/research-report/gnrh-agonists-and-antagonists-drugs-market
77. GnRH Agonist Market Report 2025 - Industry Size & Share Analysis, accessed August 11, 2025, https://www.thebusinessresearchcompany.com/report/gonadotropin-releasing-hormone-gnrh-agonist-global-market-report
78. GnRH Analogue Market Size, Share, Growth, Statistics Report 2033, accessed August 11, 2025, https://datahorizzonresearch.com/gnrh-analogue-market-7433
79. GnRH antagonists in ovarian stimulation for IVF - Oxford Academic, accessed August 11, 2025, https://academic.oup.com/humupd/article/12/4/333/2182140
80. The use of oral GnRH antagonists to inhibit the LH surge in women ..., accessed August 11, 2025, https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2428342
81. Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial | BMJ Open, accessed August 11, 2025, https://bmjopen.bmj.com/content/12/6/e052043
82. Oral GnRH antagonists for ovulation suppression during ovarian stimulation protocols: systemic review and meta-analysis - PubMed, accessed August 11, 2025, https://pubmed.ncbi.nlm.nih.gov/40327246/
83. The novel oral gonadotropin‐releasing hormone receptor antagonist ..., accessed August 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8967300/